Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by FarmerBetsyon Sep 02, 2023 1:39pm
116 Views
Post# 35617523

RE:PIPE latest financing SEC

RE:PIPE latest financing SECSince they started trading on the Nasdaq more than a year ago under 1 million shares total prior to 07/17, (1.4) million shares. Interesting some folks still trying to question whether any monkey business went on or not. The insiders have just shown what they will do so don't be surprized down the road. Not difficult to see what mpt and directors have done with delays, slopiness in all kinds of areas, but really nails it when they participate in these placements. In the interest of themselves clearly and selective investors. Let's see what the SEC and other authorities can come up with, nothing to lose at this point as the Intergrity and Ethics of Promis mpt is clear. As another investor pointed out to me probably the real reason they got rid of the tsx was to reduce the risk of investigations.  
<< Previous
Bullboard Posts
Next >>